Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

1.

Glatiramer acetate (GA), the immunomodulatory drug, inhibits inflammatory mediators and collagen degradation in osteoarthritis (OA) cartilage.

Attur M, Millman JS, Dave MN, Al-Mussawir HE, Patel J, Palmer G, Abramson SB.

Osteoarthritis Cartilage. 2011 Sep;19(9):1158-64. doi: 10.1016/j.joca.2011.06.006. Epub 2011 Jun 26.

2.

Stigmasterol: a phytosterol with potential anti-osteoarthritic properties.

Gabay O, Sanchez C, Salvat C, Chevy F, Breton M, Nourissat G, Wolf C, Jacques C, Berenbaum F.

Osteoarthritis Cartilage. 2010 Jan;18(1):106-16. doi: 10.1016/j.joca.2009.08.019. Epub 2009 Sep 15.

3.

MicroRNA-558 regulates the expression of cyclooxygenase-2 and IL-1β-induced catabolic effects in human articular chondrocytes.

Park SJ, Cheon EJ, Kim HA.

Osteoarthritis Cartilage. 2013 Jul;21(7):981-9. doi: 10.1016/j.joca.2013.04.012. Epub 2013 Apr 20.

4.

Aceclofenac increases the synthesis of interleukin 1 receptor antagonist and decreases the production of nitric oxide in human articular chondrocytes.

Maneiro E, López-Armada MJ, Fernández-Sueiro JL, Lema B, Galdo F, Blanco FJ.

J Rheumatol. 2001 Dec;28(12):2692-9.

PMID:
11764219
5.

Glatiramer acetate inhibits degradation of collagen II by suppressing the activity of interferon regulatory factor-1.

Lu H, Zeng C, Zhao H, Lian L, Dai Y.

Biochem Biophys Res Commun. 2014 Jun 6;448(3):323-8. doi: 10.1016/j.bbrc.2014.03.041. Epub 2014 Mar 18.

PMID:
24657155
6.

Prostaglandin E2 exerts catabolic effects in osteoarthritis cartilage: evidence for signaling via the EP4 receptor.

Attur M, Al-Mussawir HE, Patel J, Kitay A, Dave M, Palmer G, Pillinger MH, Abramson SB.

J Immunol. 2008 Oct 1;181(7):5082-8. Erratum in: J Immunol. 2009 Jul 15;183(2):1496.

7.

Sclareol exerts anti-osteoarthritic activities in interleukin-1β-induced rabbit chondrocytes and a rabbit osteoarthritis model.

Zhong Y, Huang Y, Santoso MB, Wu LD.

Int J Clin Exp Pathol. 2015 Mar 1;8(3):2365-74. eCollection 2015.

8.

Activation of matrix metalloproteinases 2, 9, and 13 by activated protein C in human osteoarthritic cartilage chondrocytes.

Jackson MT, Moradi B, Smith MM, Jackson CJ, Little CB.

Arthritis Rheumatol. 2014 Jun;66(6):1525-36. doi: 10.1002/art.38401.

9.

The increased synthesis of inducible nitric oxide inhibits IL-1ra synthesis by human articular chondrocytes: possible role in osteoarthritic cartilage degradation.

Pelletier JP, Mineau F, Ranger P, Tardif G, Martel-Pelletier J.

Osteoarthritis Cartilage. 1996 Mar;4(1):77-84.

PMID:
8731398
10.

Variable effects of 3 different chondroitin sulfate compounds on human osteoarthritic cartilage/chondrocytes: relevance of purity and production process.

Tat SK, Pelletier JP, Mineau F, Duval N, Martel-Pelletier J.

J Rheumatol. 2010 Mar;37(3):656-64. doi: 10.3899/jrheum.090696. Epub 2010 Jan 28.

PMID:
20110528
11.

The chondroprotective agent ITZ-1 inhibits interleukin-1beta-induced matrix metalloproteinase-13 production and suppresses nitric oxide-induced chondrocyte death.

Kimura H, Yukitake H, Suzuki H, Tajima Y, Gomaibashi K, Morimoto S, Funabashi Y, Yamada K, Takizawa M.

J Pharmacol Sci. 2009 Jun;110(2):201-11.

13.

Piperine inhibits IL-β induced expression of inflammatory mediators in human osteoarthritis chondrocyte.

Ying X, Chen X, Cheng S, Shen Y, Peng L, Xu HZ.

Int Immunopharmacol. 2013 Oct;17(2):293-9. doi: 10.1016/j.intimp.2013.06.025. Epub 2013 Jul 6.

PMID:
23838114
14.

Regulation by reactive oxygen species of interleukin-1beta, nitric oxide and prostaglandin E(2) production by human chondrocytes.

Mathy-Hartert M, Deby-Dupont GP, Reginster JY, Ayache N, Pujol JP, Henrotin YE.

Osteoarthritis Cartilage. 2002 Jul;10(7):547-55.

16.

The anti-inflammatory and matrix restorative mechanisms of platelet-rich plasma in osteoarthritis.

Sundman EA, Cole BJ, Karas V, Della Valle C, Tetreault MW, Mohammed HO, Fortier LA.

Am J Sports Med. 2014 Jan;42(1):35-41. doi: 10.1177/0363546513507766. Epub 2013 Nov 5.

PMID:
24192391
17.

SKI306X inhibition of glycosaminoglycan degradation in human cartilage involves down-regulation of cytokine-induced catabolic genes.

Choi CH, Kim TH, Sung YK, Choi CB, Na YI, Yoo H, Jun JB.

Korean J Intern Med. 2014 Sep;29(5):647-55. doi: 10.3904/kjim.2014.29.5.647. Epub 2014 Aug 28.

18.
19.

Soluble biglycan: a potential mediator of cartilage degradation in osteoarthritis.

Barreto G, Soininen A, Ylinen P, Sandelin J, Konttinen YT, Nordström DC, Eklund KK.

Arthritis Res Ther. 2015 Dec 24;17:379. doi: 10.1186/s13075-015-0902-0.

20.

Differential effects of the antioxidant n-acetylcysteine on the production of catabolic mediators in IL-1beta-stimulated human osteoarthritic synoviocytes and chondrocytes.

Roman-Blas JA, Contreras-Blasco MA, Largo R, Alvarez-Soria MA, Castañeda S, Herrero-Beaumont G.

Eur J Pharmacol. 2009 Nov 25;623(1-3):125-31. doi: 10.1016/j.ejphar.2009.09.016. Epub 2009 Sep 16.

PMID:
19765584

Supplemental Content

Support Center